Literature DB >> 32194247

Exuberant Plasmocytosis in Bronchoalveolar Lavage Specimen of the First Patient Requiring Extracorporeal Membrane Oxygenation for SARS-CoV-2 in Europe.

Marco Giani1, Davide Seminati2, Alberto Lucchini1, Giuseppe Foti1, Fabio Pagni3.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32194247      PMCID: PMC7118681          DOI: 10.1016/j.jtho.2020.03.008

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


× No keyword cloud information.
To the Editor: The arrival of the coronavirus disease 2019 (COVID-19) epidemic to Europe introduced a new scenario in the differential diagnosis of infectious diseases that pathologists may encounter in cytologic specimens, such as those in bronchoalveolar lavage (BAL). Owing to the urgent turnaround time that the clinical contest of these particular tests requires, we would like to report to clinicians the following peculiar findings, adding them to the previously published list of pathologic findings related to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. On February 17, a 66-year-old male patient presented to the emergency department of a hospital in the north of Italy with a 2-day history of fatigue and fever. He had no respiratory symptoms, and his chest radiograph result was negative. The day after, he progressively developed respiratory distress and hypoxia, and a new chest radiograph image revealed bilateral infiltrates. After a failed noninvasive ventilation trial, he was sedated and endotracheally intubated. Computed tomography scan images revealed bilateral consolidation with ground-glass attenuation in the nondependent areas. Progressive worsening of hypoxemia (up to 47 mm Hg of the ratio of partial pressure of arterial oxygen to fraction of inspired oxygen) was also observed in the patient. Our Extracorporeal Membrane Oxygenation team was called to retrieve the patient. The patient was transferred to our institution after starting venovenous extracorporeal support. Real-time polymerase chain reaction on BAL specimen revealed positivity for SARS-CoV-2. The BAL specimen was sent for pathologic examination as well (Fig. 1 A). The fluid was cytospinned and stained by May-Grünwald-Giemsa, Papanicolaou, and Perls (Prussian blue) methods. A cell block was produced for immunohistochemical staining (CD3, CD138, CD20, and kappa and lambda immunoglobulin light chains on a Dako Omnis platform, Glostrup, Denmark). The morphologic analysis revealed fibrino-hematic material with scattered alveolar macrophages and a predominantly large number of activated plasma cells (CD138+, Fig.1 C,D) with occasional plasmablastic features, admixed with T lymphocytes (CD3+) and scattered B cells (CD20+). Desquamated pneumocytes, multinucleated syncytial cells, and hyaline material were not appreciated; however, occasional alveolar macrophages revealing nuclear clearing or intranuclear cytopathic inclusions attributable to SARS-CoV-2 were easily found (Fig. 1 B). Common morphologic features of viral infection include cytomegaly, syncytia formation, and intracytoplasmic and intranuclear inclusions, but different viruses (adenovirus, respiratory syncytial virus, influenza, parainfluenza, herpes simplex virus, cytomegalovirus, varicella-zoster virus, and measles) may cause overlapping cytomorphologic changes. In 2009 influenza A virus subtype H1N1 pneumonia associated with acute respiratory distress syndrome, cells with eccentric nuclei and paranuclear vacuole were described; however, those cells proved to be reactive immature type II pneumocytes (CD138−) under electron microscopy, probably with a reparative role. In the COVID-19 BAL specimen, dramatically activated plasma cells revoked immune elements frequently found in extrinsic allergic alveolitis, drug-induced pneumonia, aspergillosis, and specific subgroups of lymphomas, such as lymphomatoid granulomatosis or primary effusion lymphoma. At the moment, there are no specific therapeutics approved by the Food and Drug Administration, but the peculiar abundance of CD138+ plasma cells in COVID-19 may be a relevant feature; indeed COVID-19 and SARS, both caused by coronaviruses, are characterized by an overexuberant inflammatory response. On the basis of this finding, the empiric combined use of antivirals and anti-inflammatory drugs is under study, even though previous studies on the 2009 influenza A virus subtype H1N1 have not reported evidence of beneficial effects of corticosteroids, which are often administered to patients with acute respiratory distress syndrome secondary to viral pneumonia. ,
Figure 1

(A) Cytospin of coronavirus disease 2019 bronchoalveolar lavage specimen revealing many clusters of activated plasma cells (Papanicolaou, ×40). (B) Alveolar macrophage intranuclear cytopathic inclusion in severe acute respiratory syndrome coronavirus 2 infection (Papanicolaou, ×100, courtesy of Dr. Francesca Bono). (C, D) Groups of polyclonal CD138-positive plasma cells (cell block, hematoxylin and eosin, ×20; CD138 staining, ×40).

(A) Cytospin of coronavirus disease 2019 bronchoalveolar lavage specimen revealing many clusters of activated plasma cells (Papanicolaou, ×40). (B) Alveolar macrophage intranuclear cytopathic inclusion in severe acute respiratory syndrome coronavirus 2 infection (Papanicolaou, ×100, courtesy of Dr. Francesca Bono). (C, D) Groups of polyclonal CD138-positive plasma cells (cell block, hematoxylin and eosin, ×20; CD138 staining, ×40).
  5 in total

1.  Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome.

Authors:  Christian Brun-Buisson; Jean-Christophe M Richard; Alain Mercat; Anne C M Thiébaut; Laurent Brochard
Journal:  Am J Respir Crit Care Med       Date:  2011-03-04       Impact factor: 21.405

2.  A case of ARDS associated with influenza A - H1N1 infection treated with extracorporeal respiratory support.

Authors:  G Grasselli; G Foti; N Patroniti; A Giuffrida; B Cortinovis; A Zanella; F Pagni; M Mergoni; A Pesci; A Pesenti
Journal:  Minerva Anestesiol       Date:  2009-12       Impact factor: 3.051

3.  Diagnosis of Infectious Diseases in the Lower Respiratory Tract: A Cytopathologist's Perspective.

Authors:  Rebecca J Baldassarri; Deepika Kumar; Stephen Baldassarri; Guoping Cai
Journal:  Arch Pathol Lab Med       Date:  2018-09-11       Impact factor: 5.534

4.  COVID-19: combining antiviral and anti-inflammatory treatments.

Authors:  Justin Stebbing; Anne Phelan; Ivan Griffin; Catherine Tucker; Olly Oechsle; Dan Smith; Peter Richardson
Journal:  Lancet Infect Dis       Date:  2020-02-27       Impact factor: 25.071

5.  Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer.

Authors:  Sufang Tian; Weidong Hu; Li Niu; Huan Liu; Haibo Xu; Shu-Yuan Xiao
Journal:  J Thorac Oncol       Date:  2020-02-28       Impact factor: 15.609

  5 in total
  23 in total

Review 1.  COVID-19-Associated Acute Respiratory Distress Syndrome: Lessons from Tissues and Cells.

Authors:  Elizabeth A Middleton; Guy A Zimmerman
Journal:  Crit Care Clin       Date:  2021-05-26       Impact factor: 3.598

2.  Comprehensive evaluation of bronchoalveolar lavage from patients with severe COVID-19 and correlation with clinical outcomes.

Authors:  Ian Gelarden; Jessica Nguyen; Juehua Gao; Qing Chen; Luisa Morales-Nebreda; Richard Wunderink; Lin Li; Joan S Chmiel; MaryAnn Hrisinko; Laura Marszalek; Sumaiya Momnani; Pinal Patel; Ricardo Sumugod; Qi Chao; Lawrence J Jennings; Teresa R Zembower; Peng Ji; Yi-Hua Chen
Journal:  Hum Pathol       Date:  2021-04-24       Impact factor: 3.526

3.  Statins as early therapy to mitigate COVID-19 (SARS-CoV-2)-associated ARDS and cytokine storm syndrome - time is of the essence.

Authors:  Narci Teoh; Geoff Farrell
Journal:  J Clin Transl Res       Date:  2020-04-18

Review 4.  Pulmonary pathology and COVID-19: lessons from autopsy. The experience of European Pulmonary Pathologists.

Authors:  Fiorella Calabrese; Federica Pezzuto; Francesco Fortarezza; Paul Hofman; Izidor Kern; Angel Panizo; Jan von der Thüsen; Sergei Timofeev; Gregor Gorkiewicz; Francesca Lunardi
Journal:  Virchows Arch       Date:  2020-07-09       Impact factor: 4.064

5.  International perspectives: Impact of the COVID-19 pandemic on cytology.

Authors:  Esther Diana Rossi; Liron Pantanowitz
Journal:  Cancer Cytopathol       Date:  2020-04-07       Impact factor: 5.284

6.  Delayed diagnosis of COVID-19 in a 34-year-old man with atypical presentation.

Authors:  Timothy J Harkin; Kevin M Rurak; John Martins; Corey Eber; Arnold H Szporn; Mary Beth Beasley
Journal:  Lancet Respir Med       Date:  2020-05-18       Impact factor: 30.700

7.  Alveolar lymphocytosis with plasmacytosis in severe COVID-19.

Authors:  G Voiriot; A Fajac; A Gibelin; A Parrot; M Fartoukh
Journal:  Respir Med Res       Date:  2020-08-14

8.  Nursing Activities Score is increased in COVID-19 patients.

Authors:  Alberto Lucchini; Marco Giani; Stefano Elli; Silvia Villa; Roberto Rona; Giuseppe Foti
Journal:  Intensive Crit Care Nurs       Date:  2020-04-23       Impact factor: 3.072

9.  Cytopathology of bronchoalveolar lavages in COVID___19 pneumonia: A pilot study.

Authors:  Valentina Canini; Francesca Bono; Paolo Calzavacca; Giulia Capitoli; Giuseppe Foti; Filippo Fraggetta; Stefania Galimberti; Andrea Gianatti; Marco Giani; Ahmed Nasr; Giuseppe Paciocco; Fabio Pagni; Roberto Rona; Vincenzo L'Imperio
Journal:  Cancer Cytopathol       Date:  2021-03-10       Impact factor: 4.264

10.  Extracorporeal Membrane Oxygenation Used in Acute Respiratory Distress Syndrome with COVID-19: A Systematic Review and Meta-Analysis.

Authors:  Novia Kusumawardhani; Ivana Purnama Dewi; Budi Baktijasa Dharmadjati
Journal:  J Saudi Heart Assoc       Date:  2021-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.